Ulrich Jäger

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +10

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka et al. · Blood · 2014 · 502 citations

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

Antonina V. Kurtova, Kumudha Balakrishnan, Rong Chen et al. · Blood · 2009 · 315 citations · Full text

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt et al. · Blood · 2014 · 274 citations · Full text

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler et al. · Journal of Clinical Oncology · 2009 · 270 citations · Full text